Do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?

Abstract Background Betamethasone (BMZ) is used to accelerate fetal lung maturation in women with threatened preterm birth, but its efficacy is variable and limited by the lack of patient individualization in its dosing and administration. To determine sources of variability and potential opportunit...

Full description

Bibliographic Details
Main Authors: Mary T. Kinney, Sara K. Quinney, Hayley K. Trussell, Larissa L. Silva, Sherrine A. Ibrahim, David M. Haas
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Pregnancy and Childbirth
Subjects:
Online Access:https://doi.org/10.1186/s12884-021-03949-5
id doaj-43da1ec139b84f27bb3928be57d23a83
record_format Article
spelling doaj-43da1ec139b84f27bb3928be57d23a832021-06-27T11:17:15ZengBMCBMC Pregnancy and Childbirth1471-23932021-06-012111710.1186/s12884-021-03949-5Do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?Mary T. Kinney0Sara K. Quinney1Hayley K. Trussell2Larissa L. Silva3Sherrine A. Ibrahim4David M. Haas5Division of Clinical Pharmacology, Indiana University School of MedicineDivision of Clinical Pharmacology, Indiana University School of MedicineDepartment of Obstetrics and Gynecology, Indiana University School of MedicineDivision of Clinical Pharmacology, Indiana University School of MedicineDepartment of Obstetrics and Gynecology, Indiana University School of MedicineDivision of Clinical Pharmacology, Indiana University School of MedicineAbstract Background Betamethasone (BMZ) is used to accelerate fetal lung maturation in women with threatened preterm birth, but its efficacy is variable and limited by the lack of patient individualization in its dosing and administration. To determine sources of variability and potential opportunities for individualization of therapy, the objective of this study was to evaluate maternal factors associated with development of neonatal respiratory distress syndrome (RDS) in a cohort of women who received betamethasone. Methods This study prospectively enrolled women, gestational ages 23–34 weeks, who received betamethasone for threatened preterm birth. Maternal demographics, prenatal history, and neonatal outcomes were abstracted from hospital records. RDS was the primary outcome. Associations between RDS diagnosis and maternal demographics, prenatal history, and betamethasone dosing were evaluated in a case-control analysis and multivariable regression adjusted for gestational age at delivery. Secondary analyses limited the cohort to women who delivered within 1 or 2 weeks of betamethasone dosing. Results Of 209 deliveries, 90 (43 %) resulted in neonatal RDS. Within the overall cohort and controlling for gestational age at birth, RDS was only associated with cesarean births compared to vaginal births (adjusted OR 1.17 [1.06–1.29]). Route of delivery was also the only significant factor related to RDS in the 83 neonates delivered within 7 days of BMZ dosing. However, among 101 deliveries within 14 days of betamethasone dosing and controlling for gestational age at birth, women who experienced preterm premature rupture of membranes (PPROM) had lower RDS rates than those without PPROM (57.9 % vs. 80.2 %, adjusted OR 0.81 [0.67–0.99]). Maternal age, BMI, race, and ethnicity were not associated with RDS in the regression models. Conclusions Of maternal characteristics analyzed, only delivery by cesarean was associated with neonatal RDS after antenatal betamethasone use.https://doi.org/10.1186/s12884-021-03949-5BetamethasoneAntenatal corticosteroidsPreterm birthRespiratory distress syndrome (RDS)Cesarean
collection DOAJ
language English
format Article
sources DOAJ
author Mary T. Kinney
Sara K. Quinney
Hayley K. Trussell
Larissa L. Silva
Sherrine A. Ibrahim
David M. Haas
spellingShingle Mary T. Kinney
Sara K. Quinney
Hayley K. Trussell
Larissa L. Silva
Sherrine A. Ibrahim
David M. Haas
Do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?
BMC Pregnancy and Childbirth
Betamethasone
Antenatal corticosteroids
Preterm birth
Respiratory distress syndrome (RDS)
Cesarean
author_facet Mary T. Kinney
Sara K. Quinney
Hayley K. Trussell
Larissa L. Silva
Sherrine A. Ibrahim
David M. Haas
author_sort Mary T. Kinney
title Do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?
title_short Do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?
title_full Do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?
title_fullStr Do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?
title_full_unstemmed Do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?
title_sort do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?
publisher BMC
series BMC Pregnancy and Childbirth
issn 1471-2393
publishDate 2021-06-01
description Abstract Background Betamethasone (BMZ) is used to accelerate fetal lung maturation in women with threatened preterm birth, but its efficacy is variable and limited by the lack of patient individualization in its dosing and administration. To determine sources of variability and potential opportunities for individualization of therapy, the objective of this study was to evaluate maternal factors associated with development of neonatal respiratory distress syndrome (RDS) in a cohort of women who received betamethasone. Methods This study prospectively enrolled women, gestational ages 23–34 weeks, who received betamethasone for threatened preterm birth. Maternal demographics, prenatal history, and neonatal outcomes were abstracted from hospital records. RDS was the primary outcome. Associations between RDS diagnosis and maternal demographics, prenatal history, and betamethasone dosing were evaluated in a case-control analysis and multivariable regression adjusted for gestational age at delivery. Secondary analyses limited the cohort to women who delivered within 1 or 2 weeks of betamethasone dosing. Results Of 209 deliveries, 90 (43 %) resulted in neonatal RDS. Within the overall cohort and controlling for gestational age at birth, RDS was only associated with cesarean births compared to vaginal births (adjusted OR 1.17 [1.06–1.29]). Route of delivery was also the only significant factor related to RDS in the 83 neonates delivered within 7 days of BMZ dosing. However, among 101 deliveries within 14 days of betamethasone dosing and controlling for gestational age at birth, women who experienced preterm premature rupture of membranes (PPROM) had lower RDS rates than those without PPROM (57.9 % vs. 80.2 %, adjusted OR 0.81 [0.67–0.99]). Maternal age, BMI, race, and ethnicity were not associated with RDS in the regression models. Conclusions Of maternal characteristics analyzed, only delivery by cesarean was associated with neonatal RDS after antenatal betamethasone use.
topic Betamethasone
Antenatal corticosteroids
Preterm birth
Respiratory distress syndrome (RDS)
Cesarean
url https://doi.org/10.1186/s12884-021-03949-5
work_keys_str_mv AT marytkinney domaternaldemographicsandprenatalhistoryimpacttheefficacyofbetamethasonetherapyforthreatenedpretermlabor
AT sarakquinney domaternaldemographicsandprenatalhistoryimpacttheefficacyofbetamethasonetherapyforthreatenedpretermlabor
AT hayleyktrussell domaternaldemographicsandprenatalhistoryimpacttheefficacyofbetamethasonetherapyforthreatenedpretermlabor
AT larissalsilva domaternaldemographicsandprenatalhistoryimpacttheefficacyofbetamethasonetherapyforthreatenedpretermlabor
AT sherrineaibrahim domaternaldemographicsandprenatalhistoryimpacttheefficacyofbetamethasonetherapyforthreatenedpretermlabor
AT davidmhaas domaternaldemographicsandprenatalhistoryimpacttheefficacyofbetamethasonetherapyforthreatenedpretermlabor
_version_ 1721357991926562816